RHYTHM Biosciences Ltd (RHY) - Net Assets

Latest as of December 2025: AU$2.14 Million AUD ≈ $1.52 Million USD

Based on the latest financial reports, RHYTHM Biosciences Ltd (RHY) has net assets worth AU$2.14 Million AUD (≈ $1.52 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$3.10 Million ≈ $2.19 Million USD) and total liabilities (AU$955.41K ≈ $676.01K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are RHYTHM Biosciences Ltd's assets to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	AU$2.14 Million
% of Total Assets	69.17%
Annual Growth Rate	-9.16%
5-Year Change	-61.34%
10-Year Change	N/A
Growth Volatility	198.62

RHYTHM Biosciences Ltd - Net Assets Trend (2017–2025)

This chart illustrates how RHYTHM Biosciences Ltd's net assets have evolved over time, based on quarterly financial data. Also explore RHYTHM Biosciences Ltd balance sheet assets for the complete picture of this company's asset base.

Annual Net Assets for RHYTHM Biosciences Ltd (2017–2025)

The table below shows the annual net assets of RHYTHM Biosciences Ltd from 2017 to 2025. For live valuation and market cap data, see RHYTHM Biosciences Ltd (RHY) market capitalisation.

Year	Net Assets	Change
2025-06-30	AU$659.89K ≈ $466.92K	-23.90%
2024-06-30	AU$867.17K ≈ $613.58K	-85.24%
2023-06-30	AU$5.87 Million ≈ $4.16 Million	-20.31%
2022-06-30	AU$7.37 Million ≈ $5.22 Million	+331.92%
2021-06-30	AU$1.71 Million ≈ $1.21 Million	-7.39%
2020-06-30	AU$1.84 Million ≈ $1.30 Million	-68.49%
2019-06-30	AU$5.85 Million ≈ $4.14 Million	-29.53%
2018-06-30	AU$8.30 Million ≈ $5.87 Million	+483.41%
2017-06-30	AU$1.42 Million ≈ $1.01 Million	--

Equity Component Analysis

This analysis shows how different components contribute to RHYTHM Biosciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 4243141700.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component	Amount	Percentage
Common Stock	AU$37.75 Million	5721.18%
Other Comprehensive Income	AU$5.41 Million	819.81%
Other Components	AU$1.00	0.00%
Total Equity	AU$659.89K	100.00%

RHYTHM Biosciences Ltd Competitors by Market Cap

The table below lists competitors of RHYTHM Biosciences Ltd ranked by their market capitalization.

Company	Market Cap
Labiana Health S.A. MC:LAB	$32.50 Million
Impresa - Sociedade Gestora de Participações Sociais S.A LS:IPR	$32.51 Million
Avrupa Yatirim Holding AS IS:AVHOL	$32.52 Million
Grand Ocean Retail Group Ltd TW:5907	$32.52 Million
Vardhman Acrylics Limited NSE:VARDHACRLC	$32.48 Million
EasyJet PLC LSE:EZJ	$32.47 Million
Far East Gold Ltd AU:FEG	$32.46 Million
Profoto Holding AB ST:PRFO	$32.46 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in RHYTHM Biosciences Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 867,166 to 659,892, a change of -207,274 (-23.9%).
Net loss of 3,829,371 reduced equity.
Share repurchases of 3,500,050 reduced equity.
Other comprehensive income increased equity by 316,596.
Other factors increased equity by 6,805,551.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	AU$-3.83 Million	-580.3%
Share Repurchases	AU$3.50 Million	-530.4%
Other Comprehensive Income	AU$316.60K	+47.98%
Other Changes	AU$6.81 Million	+1031.31%
Total Change	AU$-	-23.90%

Book Value vs Market Value Analysis

This analysis compares RHYTHM Biosciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 57.12x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 11.60x to 57.12x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-06-30	AU$0.01	AU$0.14	x
2018-06-30	AU$0.09	AU$0.14	x
2019-06-30	AU$0.05	AU$0.14	x
2020-06-30	AU$0.02	AU$0.14	x
2021-06-30	AU$0.01	AU$0.14	x
2022-06-30	AU$0.03	AU$0.14	x
2023-06-30	AU$0.03	AU$0.14	x
2024-06-30	AU$0.00	AU$0.14	x
2025-06-30	AU$0.00	AU$0.14	x

Capital Efficiency Dashboard

This dashboard shows how efficiently RHYTHM Biosciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -580.30%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -119.97%
• Asset Turnover: 1.13x
• Equity Multiplier: 4.29x
Recent ROE (-580.30%) is below the historical average (-256.18%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2017	-5.07%	0.00%	0.00x	1.09x	AU$-214.41K
2018	-21.12%	-2718.67%	0.01x	1.02x	AU$-2.58 Million
2019	-43.52%	-247.67%	0.17x	1.06x	AU$-3.13 Million
2020	-218.28%	-4023.00%	0.04x	1.44x	AU$-4.21 Million
2021	-387.39%	-596.21%	0.36x	1.80x	AU$-6.78 Million
2022	-119.29%	-362.34%	0.29x	1.14x	AU$-9.53 Million
2023	-139.89%	-265.44%	0.40x	1.31x	AU$-8.81 Million
2024	-790.74%	-405.74%	1.11x	1.75x	AU$-6.94 Million
2025	-580.30%	-119.97%	1.13x	4.29x	AU$-3.90 Million

Industry Comparison

This section compares RHYTHM Biosciences Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

Industry: Diagnostics & Research
Average net assets among peers: $260,295,060
Average return on equity (ROE) among peers: -35.40%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
RHYTHM Biosciences Ltd (RHY)	AU$2.14 Million	-5.07%	0.45x	$32.49 Million
Australian Clinical Labs Ltd (ACL)	$14.12 Million	-170.17%	7.56x	$256.90 Million
Bcal Diagnostics Ltd (BDX)	$9.64 Million	-35.12%	0.10x	$21.65 Million
Cryosite Ltd (CTE)	$3.87 Million	-25.46%	0.05x	$39.72 Million
Genetic Signatures Ltd (GSS)	$16.49 Million	-16.20%	0.07x	$14.14 Million
Genetic Technologies Ltd (GTG)	$20.83 Million	-26.20%	0.16x	$4.01 Million
Healius Ltd (HLS)	$2.50 Billion	3.13%	0.53x	$254.32 Million
Imagion Biosystems Ltd (IBX)	$13.31 Million	-45.28%	0.06x	$5.90 Million
Integral Diagnostics Ltd (IDX)	$2.54 Million	127.10%	0.00x	$585.79 Million
Inoviq Ltd (IIQ)	$2.83 Million	-115.42%	0.16x	$32.37 Million
Microba Life Sciences Ltd (MAP)	$14.94 Million	-50.37%	0.24x	$32.75 Million

About RHYTHM Biosciences Ltd

AU:RHY Australia Diagnostics & Research

Market Cap

$32.49 Million

AU$45.92 Million AUD

Market Cap Rank

#23455 Global

#927 in Australia

Share Price

AU$0.14

Change (1 day)

+3.70%

52-Week Range

AU$0.05 - AU$0.26

All Time High

AU$2.00